CD22 targeting antibody-drug conjugate (AbTis)

N/A

Report date: 2025/06/11 10:21:33

Base Information

Drug NameCD22 targeting antibody-drug conjugate (AbTis)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD22 modulators
TargetsCD22
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbTis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAbTis Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A